Masimo Named One of Fast Company’s Most Innovative Companies in North America

Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, is thrilled to announce its recognition as one of Fast Company’s Most Innovative Companies in North America for 2024. This prestigious accolade is especially meaningful given Masimo’s notable breakthroughs and the company’s commitment to improve people’s lives through innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319317729/en/

Masimo is one of Fast Company's Most Innovative Companies in North America for 2024. (Graphic: Business Wire)

“We are honored to be recognized by Fast Company as one of the top 10 Most Innovative Companies in North America for 2024,” said Joe Kiani, Founder and CEO of Masimo. “This recognizes our ongoing commitment to driving innovation to improve lives. Since our founding 35 years ago, we have made solving what others thought unsolvable our task, and fortunately, thanks to our incredible team, we have solved many ‘unsolvable problems.’ Our solutions have helped improve patient care and reduce the cost of care. We intend to continue to innovate to usher in 22^nd century healthcare in this decade.”

Masimo’s inclusion in this respected list highlights its unwavering dedication to innovation and the transformative impact of its technologies in the healthcare sector. Masimo has been recognized as one of the 10 most innovative organizations in the North America sector, a testament to its leadership in advancing patient care through cutting-edge and innovative solutions. In their announcement, Fast Company highlighted several Masimo breakthrough technologies that received FDA clearance in 2023, including Opioid Halo, an opioid overdose and prevention solution that is the first and only FDA-authorized device to alert you in the event of an opioid overdose; Stork, a revolutionary baby monitor that provides continuous, accurate monitoring, with alarms, based on Masimo’s foundational pulse oximetry technology; and Masimo W1, a first-of-its-kind wearable offering accurate, continuous health data and now available both in a consumer sport-oriented version and as a medical watch – the first FDA-cleared watch to provide continuous real-time oxygen saturation and pulse rate for over-the-counter and prescription use.